1. Home
  2. CAPR vs SCTX Comparison

CAPR vs SCTX Comparison

Compare CAPR & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$7.60

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Logo Scribe Therapeutics Inc. Common Stock

SCTX

Scribe Therapeutics Inc. Common Stock

N/A

Current Price

$12.05

Market Cap

297.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
SCTX
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
584.9M
297.2M
IPO Year
2011
2026

Fundamental Metrics

Financial Performance
Metric
CAPR
SCTX
Price
$7.60
$12.05
Analyst Decision
Buy
Strong Buy
Analyst Count
10
4
Target Price
$27.25
★ $57.00
AVG Volume (30 Days)
★ 4.2M
360.4K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$85.77
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.96
$12.58
52 Week High
$40.37
$39.60

Technical Indicators

Market Signals
Indicator
CAPR
SCTX
Relative Strength Index (RSI) 48.38 31.53
Support Level $7.78 N/A
Resistance Level $10.62 $18.30
Average True Range (ATR) 1.18 1.61
MACD -0.11 -0.18
Stochastic Oscillator 19.61 3.50

Price Performance

Historical Comparison
CAPR
SCTX

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About SCTX Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Share on Social Networks: